Optimizing the Use of Checkpoint Inhibitors in NSCLC - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Optimizing the Use of Checkpoint Inhibitors in NSCLC

Rallying the Troops

Not a member of My prIME? Join now for instant access.

View downloadable slides from our live meeting series for clinicians who treat and manage veterans with lung cancer. Get the latest updates on immunotherapeutic treatment options approved by the US Food and Drug Administration and adverse event management in patients with early-stage and advanced non-small cell lung cancer (NSCLC).

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Mar 16, 2018

Expiration Date

Mar 16, 2019

Optimizing the use of checkpoint inhibitors in NSCLC
Corey Carter, MD and Naiyer Rizvi, MD

This activity is designed to meet the needs of medical, surgical, and radiation oncologists, as well as advanced practitioners and mid-level providers who treat/manage patients in the VA system or in the VA Choice programs with lung cancer.

After successful completion of this educational activity, participants should be able to:

  • Discuss the mechanisms of action of checkpoint inhibitors used in the treatment of lung cancer
  • Design optimal strategies for the treatment of NSCLC that incorporate the use of checkpoint inhibitors
  • Select the appropriate strategy for managing/mitigating side effects

This educational activity is supported by grants from AstraZeneca and Merck and Co, Inc.

Enduring Material From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Carter has disclosed that he has no financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Rizvi has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Lilly, Merck, Novartis, Pfizer, and Roche. He also has ownership interest in ARMO Biosciences and Gritstone Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Kristin Tomlinson, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.